Ipsen Obtains Approval in Japan for Bylvay to Treat Pruritus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 19 2025
0mins
Source: NASDAQ.COM
Approval of Bylvay: Japan's Ministry of Health has approved Bylvay (odevixibat) for treating pruritus associated with progressive familial intrahepatic cholestasis (PFIC), a rare genetic liver disorder that causes severe itching and can lead to liver damage.
Clinical Trial Success: The approval was supported by a Phase III study showing significant improvements in bile acid levels and pruritus severity in children, with Bylvay already approved in the EU and US for PFIC and other conditions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
